Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$115.00
▼ $1.57 (-1.3%)
Market data updated: 09/29 02:35 AM
Fundamentals updated: 09/28/2026
News analyzed: 09/29/2026
Market Cap
$4.80B
Day Range
$112.30 - $118.00
52-Week Range
$32.00 - $131.24
Beta
—
Next Earnings
—
Support
$93.77
Resistance
$122.00
MANE is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+210.5% (1Y)
Strengths: 11/22 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Return on equity (ROE)
Return on equity (ROE): 57.8% — strong
Fundamental
Biggest negative driver
Daily volatility (ATR)
ATR: 5.1% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 0 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 0
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
56
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
today · $115.00
Evidence: Narrative Gap moved from -10 to 22 day-over-day
What happened after
Still awaiting outcome
today · $115.00
Evidence: FOMO score jumped from 0 to 56 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
32
Quality
No data available
Value
50
Momentum
73
Risk
48
Sentiment
62
Fundamental
58
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Veradermics, Inc. has centered on its dramatic stock performance—a 161% year-to-date rally—sparking debates over valuation and market positioning. Analysts note the company’s focus on hair loss treatments, with Q2 2026 earnings showing improved losses ($0.58/share vs. estimates) amid clinical and corporate progress. Insider selling and sector trends, including biotech’s growth potential, also drew attention, alongside Baron Capital’s bullish outlook on its disruptive market potential.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Veradermics, Incorporated. News trend score: 62. Reason: 6 of the last 20 articles are positive, versus 4 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
49
🎯 Conviction (vs. Emotion)
50
Psychology
56
Fundamentals
58
Technical
73
Valuation
50
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price rise has far outpaced the actual improvement in fundamental data.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Price (3M)
-5%
Market Narrative
72
Fundamental Reality
50
Narrative Gap
+22
🔀 Weak-Conviction Rally
Price is moving, but not accompanied by a matching rise in news attention/sentiment.
🧠 StockIQ Psychologist
The market behavior for MANE suggests a low-energy, cautious stance with no dominant psychological bias. Negative momentum and muted volume rule out FOMO or panic, while anchoring (4/20) hints at mild fixation on support. The narrative gap (-20) indicates investors may be underestimating current realities. The key question: *Is this a pause before a rebound or a sustained consolidation?*
Updated: 09/06/2026, 08:05 AM
👥 What the crowd believes
"Veradermics (MANE) Stock Looks Overvalued After Its 161% Rally"
"Veradermics Insider Sold Shares Worth $10,711,700"
"Veradermics (NYSE:MANE) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.65)"
"Veradermics Positioned to Disrupt Hair Loss Market"
🧠 Market Brain events driving this
📈 6D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
Based on the documented principles of each investor, the model estimates that Graham’s classic value framework and Bagehot’s liquidity focus both assign the highest scores, largely because the data needed for a full Graham valuation is missing while the company’s balance sheet appears strong enough to survive a credit squeeze. Mid‑range scores from Nelson, Marks (both cycle‑focused and overall), Schwager, Veblen and Loeb reflect more nuanced views, indicating a favorable cycle position but also moderate risk and mixed signals about growth translating into profit. Lower scores from Livermore and the Smith‑Fisher‑Lynch‑Housel group suggest negative trend expectations, insufficient dividend or fundamental data, and volatility that would discourage a patient holder. Overall, the divergence stems from the varying emphasis each methodology places on liquidity, cycle timing, growth evidence, and market trends, leading to a spectrum of cautiously optimistic to skeptical assessments.
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 100
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 15%
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 100
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 20%
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟢 66
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 55
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 51
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 47
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 43
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 40
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 30
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 26
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 10
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 0
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 20%
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 0
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Based on the last 163 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (8 bullish · 2 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
—
Net Margin
—
EBITDA Margin
—
ROE
57.8%
ROA
-45.9%
ROIC
—
EPS
-$111.91
Cash
$21.77M
Total Debt
—
Current Ratio
16.66
Debt/Equity
—
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Current Price
$115.00
Estimated Fair Value (DCF)
-$1,793.60
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
⚠️ Extreme
Model output is extreme — likely a data/model limitation for this stock, not a reliable fair-value read.
Year 1 Growth Rate
10.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 10.0% | $-78.79M | $-72.28M |
| 2 | 8.1% | $-85.19M | $-71.70M |
| 3 | 6.3% | $-90.51M | $-69.89M |
| 4 | 4.4% | $-94.47M | $-66.93M |
| 5 | 2.5% | $-96.84M | $-62.94M |
Base FCF (last actual year)
$-71.63M
Terminal Value
$-1.53B
Present Value of Terminal Value
$-992.47M
Enterprise Value
$-1.34B
Net Debt
$0
Equity Value
$-1.34B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
-$162.44
Tangible Book Value per Share (Tangible NAV)
-$162.44
Sentiment based on basic keywords (not AI) — 6 positive, 10 neutral, 4 negative out of the last 20 articles.
SeekingAlpha · 18.9.2026
SeekingAlpha · 15.9.2026
Yahoo · 12.9.2026
SeekingAlpha · 9.9.2026
Yahoo · 3.9.2026
Business Wire · 3.9.2026
Yahoo · 3.9.2026
Simply Wall St. · 3.9.2026
Yahoo · 2.9.2026
Simply Wall St. · 2.9.2026
Yahoo · 31.8.2026
BeInCrypto · 31.8.2026
SeekingAlpha · 27.8.2026
MT Newswires · 17.8.2026
Associated Press · 11.8.2026
Benzinga · 11.8.2026
Business Wire · 11.8.2026
Yahoo · 11.8.2026
Yahoo · 4.8.2026
Insider Monkey · 4.8.2026
Veradermics, Incorporated (MANE) currently has a StockIQ AI score of 56/100, rated "Moderate" (a partial score — based on only 6 of 7 categories, some data is currently unavailable). The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
MANE currently scores 56/100 (Moderate) across the categories we measure (a partial score — based on only 6 of 7 categories, some data is currently unavailable). StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
MANE's technical score is 73/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Return on equity (ROE): 57.8% — strong; Current ratio: 16.66; Price is above the 50-day average.
Based on the real signals StockIQ computed: ATR: 5.1% of price; Earnings per share (EPS) growth: -202.1%; Free cash flow growth: -202.4%.
StockIQ has no recorded dividend payment history for MANE.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 11 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Hollander David | Grant/Award from Employer | 1.9.2026 | 9,650 | +9,650 | — |
| Hollander David | Grant/Award from Employer | 1.9.2026 | 19,300 | +19,300 | — |
| Hollander David | Grant/Award from Employer | 1.9.2026 | 9,650 | +9,650 | — |
| Hollander David | Grant/Award from Employer | 1.9.2026 | 19,300 | +19,300 | — |
| MONTANOVA CAPITAL, LLC | Option Exercise (in-the-money) | 20.8.2026 | 0 | -149,000 | — |
| MONTANOVA CAPITAL, LLC | Option Exercise (in-the-money) | 20.8.2026 | 3,106,937 | +149,000 | — |
| MONTANOVA CAPITAL, LLC | Option Exercise (in-the-money) | 20.8.2026 | 612,033 | +151,000 | — |
| MONTANOVA CAPITAL, LLC | Option Exercise (in-the-money) | 20.8.2026 | 151,000 | -151,000 | — |
| MONTANOVA CAPITAL, LLC | Option Exercise (in-the-money) | 20.8.2026 | 151,000 | +151,000 | — |
| MONTANOVA CAPITAL, LLC | Option Exercise (in-the-money) | 20.8.2026 | 149,000 | +149,000 | — |
| MONTANOVA CAPITAL, LLC | Option Exercise (in-the-money) | 20.8.2026 | 149,000 | -149,000 | — |
| MONTANOVA CAPITAL, LLC | Open Market Sale | 19.8.2026 | 461,033 | -59,399 | $107.25 |
| MONTANOVA CAPITAL, LLC | Open Market Sale | 19.8.2026 | 2,957,937 | -690,601 | $107.25 |
| MONTANOVA CAPITAL, LLC | Open Market Sale | 19.8.2026 | 59,399 | -59,399 | $107.25 |
| MONTANOVA CAPITAL, LLC | Open Market Sale | 19.8.2026 | 690,601 | -690,601 | $107.25 |
| Durso Timothy August | Exercise of Derivative Securities | 17.8.2026 | 121,642 | +3,452 | $12.19 |
| Durso Timothy August | Open Market Sale | 17.8.2026 | 80,651 | -16,767 | $108.38 |
| Durso Timothy August | Open Market Sale | 17.8.2026 | 97,418 | -16,306 | $107.52 |
| Durso Timothy August | Open Market Sale | 17.8.2026 | 78,142 | -161 | $111.28 |
| Waldman Reid Alexander | Open Market Sale | 17.8.2026 | 171,073 | -3,000 | $109.38 |
| Waldman Reid Alexander | Exercise of Derivative Securities | 17.8.2026 | 0 | -3,452 | — |
| Waldman Reid Alexander | Exercise of Derivative Securities | 17.8.2026 | 238,324 | +3,452 | $12.19 |
| Durso Timothy August | Open Market Sale | 17.8.2026 | 113,724 | -7,918 | $106.71 |
| Waldman Reid Alexander | Open Market Sale | 17.8.2026 | 170,824 | -249 | $111.28 |
| Durso Timothy August | Open Market Sale | 17.8.2026 | 78,303 | -2,348 | $109.34 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
4,106,974 shares short as of 2026-09-15 · vs. 4,025,420 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
59.2% of trading volume this week was short selling, vs. 54.4% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology